TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02478047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only antiemetic (Ramosetron, Tropisetron and dexamethasone)
Description: The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching points ST36+CV12 plus antiemetic drug
Description: Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching points PC6+CV12 plus antiemetic drug
Description: Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching points CV13+CV12 plus antiemetic drug
Description: Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.
Study: NCT03872674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-flow humidified oxygen-delivery system (OptiFlow THRIVE)
Description: stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
Study: NCT03934762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aloe vera soup
Description: Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
Study: NCT04290637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold-water sea swimming
Description: Continue sea swimming for 4-6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No cold-water sea swimming
Description: Discontinue sea swimming for 4-6 weeks
Study: NCT03882918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101
Description: Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
Study: NCT01931046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad5-SGE-REIC/Dkk3
Description: Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad5-SGE-REIC/Dkk3
Description: Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
Study: NCT03050164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib Tablet 250mg of Hunan Kelun
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib Tablet 250mg of Hunan Kelun
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa® Tablet 250mg of AZN
Description: Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iressa® Tablet 250mg of AZN
Description: Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
Study: NCT02521480

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Stimulation
Description: TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Inactive treatment (simulation of active TMS)
Study: NCT03726476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient centered pre-op education
Description: To implement a patient centered education intervention to evaluate post-op narcotic use.
Study: NCT03202030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dentoalveolar restoration
Description: Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
Study: NCT03726476

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine preop education
Description: To implement routine patient education intervention to evaluate post-op narcotic use.
Study: NCT04262934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100.000 UI administration
Description: One oral Administration - Every month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No vitamin D administration
Description: No vitamin D administration
Study: NCT01278953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation to treat paroxysmal atrial fibrillation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation to treat paroxysmal atrial fibrillation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
Study: NCT02544789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
Study: NCT00549718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Once daily
Study: NCT04785729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib combine with Pyrrolitinib
Description: 110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
Study: NCT00549718

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lurasidone HCl
Description: Once daily
Study: NCT03620747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous
Study: NCT03999684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
Study: NCT02514330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training at 1% incline
Description: Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training at 10% incline
Description: Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
Study: NCT05492279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sheep ghee
Description: natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
Study: NCT03558724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
Study: NCT03202030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized bovine bone
Description: Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
Study: NCT00676507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lucanix™
Description: Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
Study: NCT02203149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir
Description: One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One 50 mg tablet taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One 50 mg tablet taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One 50 mg tablet taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elbasvir
Description: One 50 mg tablet taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One 50 mg tablet taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Grazoprevir
Description: One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir
Description: One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Elbasvir
Description: One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
Study: NCT01766648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far Cortical locking screw fixation
Description: Standard screw fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard screw fixation
Study: NCT03812510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101
Description: hydrogen peroxide topical solution 45%
Study: NCT00764725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional DMARD combination
Description: MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MTX plus anti-TNF
Description: MTX + infliximab; can be changed to MTX + etanercept within protocol
Study: NCT01636557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study: NCT02635204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06 Cream
Description: Twice daily topical application for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Twice daily topical application for 14 days.
Study: NCT04552470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 matching placebo tablets taken twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
Study: NCT03399383

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
Study: NCT01021111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Training with Feedback
Description: The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
Study: NCT02304003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Physiotherapy Regimen
Description: Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard follow up in primary care.
Study: NCT00759603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
Study: NCT01145560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773
Description: A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773
Description: A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03431220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device
Description: NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
Study: NCT00693706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine GSK 138842A
Description: IM injection on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: IM injection on Day 0
Study: NCT00816803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Study: NCT03603743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training in heart failure with HIIT
Description: to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training in heart failure with HIIT
Description: to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
Study: NCT03120143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small-sided ball game training with high protein intake
Description: In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small-sided ball game training with low protein intake
Description: n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
Study: NCT00519077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
Study: NCT05492279

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sunflower oil
Description: natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
Study: NCT04907838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin clamp
Description: Continous infusion insulin + glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin clamp
Description: Continous infusion insulin + glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Continuous infusion of Insulin + glucose + BQ123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Continuous infusion of Insulin + glucose + BQ123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123 + BQ788
Description: Continous infusion of insulin + glucose + BQ123 + BQ788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123 + BQ788
Description: Continous infusion of insulin + glucose + BQ123 + BQ788